Workers testing in a pharmaceutical factory
Ying Marainen, Asia Pacific director of CTSCS Business Development, said China faces challenges in the management and transportation of clinical trial materials.
The pharmaceutical industry in China has maintained sustained growth with the government prioritizing the biotech and pharmaceutical sectors.
The increasing global costs of R&D (research and development, coupled with decreased productivity, has led multinationals to outsource their clinical trials to developing countries.
Supply chain medicinal services are still not up to speed with growing numbers of third-party service providers, low-tech facilities and high costs.
Drug storage conditions vary greatly across the board. And there is still limited understanding in China of international GMP (good manufacturing practice) standards.
Statistics show that the rate of cost in distribution of pharmaceutical products in China is around 12% while the profit rate is about 1%. In more advanced economies, the cost rate is around 3% and profit rate 1.5%.
For more on this click HERE.
Source: CargoNews Asia
You must log in to post a comment.